First Quarter 2024 Business Update & Financial Results Conference Call

AMARIN®

MAY 1, 2024

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA®(VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, and guidance.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

Today's Agenda

01

First Quarter 2024 Business Update
Patrick Holt, President & CEO

02

Intellectual Property & Legal Update
Jonathan Provoost, EVP, Chief Legal & Compliance Officer

03

Clinical Data Update
Steven Ketchum, PhD, EVP, President R&D, Chief Scientific Officer

04

First Quarter 2024 Financial Results
Tom Reilly, CFO

05

Closing & Q&A
Patrick Holt, President & CEO

01

FIRST QUARTER 2024 BUSINESS UPDATE

Patrick Holt, President & CEO

Q1 2024 Business Highlights

- **European IP Extended to 2039**
  - Provides Longer Runway to Reach Total Addressable Market & Maximize Commercial Opportunity and Value for VAZKEPA
- **Europe: Continued Growth Q1 '24 vs. Q4 '23; Pricing & Reimbursement Efforts Advancing**
  - ~35% Revenue Growth; ~65% In-Market Sales Growth Q1 '24 vs. Q4 '23, led by Spain & UK
- **Continued Focus on Profitability and Cash Preservation; Quarter-End Cash Position of $308 million**
  - Stable cash position over last seven quarters
- **Secured shareholder approval for share repurchase program of up to $50 million; expected U.K. High Court approval and share repurchases commencing in Q2**

EUROPE: DELIVERED ~65% IN-MARKET SALES GROWTH IN Q1 '24 VS. Q4 '23; CONTINUED FOCUS ON REVENUE ACCELERATION, P&R PROGRESS

European IP Extension Provides Longer Runway to Reach Total Addressable Market & Maximize Commercial Opportunity and Value for VAZKEPA

A INCREASE IMPACT ON EU5

Accelerating Growth & Revenue

Spain

Broad patient uptake across all territories: +~ 91% increase in patients on therapy end of Q1

United Kingdom

Following introduction of enhanced strategy, +~28% increase in patients on therapy end of Q1

Advancing Pricing & Reimbursement Efforts

Italy

Resubmitted dossier; on-track for potential P&R in 2024

France

Plans on-track to submit strengthened dossier in 2024

Germany

Continued work on potential resubmission

B SUPPORT EFFORTS IN REST OF EUROPE

Advance Additional P&R Submissions

Greece *Belgium* *Norway*

Portugal *Austria* *Republic of Ireland*

We aim to conclude successfully on at least 5 additional P&R submissions in Rest of Europe in 2024.

Support Commercialization in Launched Markets

Netherlands *Sweden*

Finland

U.S.: IPE MARKET LEADERSHIP MARKET SHARE STABILITY CONTINUES DRIVING PROFITABILITY; ADDITIONAL HEADWINDS IMPACT Q1 REVENUES

Q1 2024:

Exclusive Accounts Represent

50%+

Of Total IPE Market Volume

- U.S. business continues to deliver significant profit
- U.S. market share has remained stable for six consecutive quarters
- Q1 revenues impacted by U.S. net selling price due to generic competition
- Increased generic competition in Q1 2024, expected to continue through the year

With a Highly Dynamic Market, Amarin is Ready to Execute Plans to Retain IPE Market Leadership & Profitability

REST OF WORLD: CONTINUED PROGRESS ON ADVANCING ACCESS & UPTAKE IN KEY MARKETS TO DRIVE PROFITABILITY

- Launched
- Regulatory Approval Achieved; P&R Efforts in Process
- Regulatory Preparations in Process

20+ Regulatory Processes Underway

Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary market to market.

02 INTELLECTUAL PROPERTY & LEGAL UPDATE

Jonathan Provoost, EVP, Chief Legal & Compliance Officer

AMARIN STRENGTHENS AND EXTENDS EUROPEAN IP FOR VAZKEPA IN EUROPE INTO 2039

- **Amarin announced two patent outcomes that, collectively, build upon and strengthen multiple layers of patent and regulatory protection for VAZKEPA within our European market into 2039.**
- Company received Decision to Grant from the European Patent Office (EPO) for a new patent covering VAZKEPA® (icosapent ethyl) that will extend VAZKEPA exclusivity until 2039.
- Follows Company's recent success in defending separate European VAZKEPA patent from third-party opposition within the EPO.
- Patents cover both the protocol and results from the landmark REDUCE-IT outcomes study.

European Patent Office

03 CLINICAL DATA UPDATE



Steven Ketchum, PhD, EVP, President R&D, Chief Scientific Officer

ACC.24 FEATURES ABSTRACTS RELATED TO REDUCE-IT, EPA SCIENCE

REDUCE-IT Post Hoc Analyses

1. **Icosapent Ethyl Reduces MACE in Patients with Elevated Triglycerides and High or Low Lipoprotein(a) Concentrations: A REDUCE-IT Subanalysis**

   KEY TAKEAWAY: IPE reduced MACE among those with either high or low LP(a) levels at baseline, reinforcing its clinical utility in these patient subpopulations.

2. **Efficacy of Icosapent Ethyl for Reducing Cardiovascular Outcomes by Baseline Low Density Lipoprotein Cholesterol Level**

   KEY TAKEAWAY: IPE reduced the rate of CV outcomes irrespective of baseline LDL-C, including in those with LDL-C <55 mg/dL.

EPA Science

1. **EPA and a High Intensity Statin Enhanced Expression of Proteins for Detoxification of Reactive Oxygen Species During Angiotensin II Challenge in Endothelial Cells**

2. **EPA and Rosuvastatin Modulate Expression of Endothelial Proteins that Regulate Function and Platelet Activity During Angiotensin II Stimulation**

3. **EPA Inhibits Lipoprotein(a) Oxidation due to Scavenging Mechanisms in Vitro**

Data featured at ACC.24 continue to support and illuminate the clinical utility and value of icosapent ethyl in treating patient sub-populations, as well as providing further evidence regarding the potential mechanistic activity of EPA in reducing cardiovascular events in at-risk patients.

04 FIRST QUARTER 2024 FINANCIAL RESULTS

Tom Reilly, CFO

MANAGING OPERATING EXPENSES
TO PARTIALLY OFFSET REVENUE DECLINE



Revenue of $57M in Q1 impacted primarily by U.S. pricing due to generic competition

- U.S. revenue of $48M; Decline driven largely by net selling price impact due to generic competition
- Q1 2024 European net product revenues were $2 million; represents ~35% net sales growth vs Q4 '23

Key Operating Expense Drivers:

- Q1 '24 $45M compared to Q1 '23 $65M; lower by $20M
- $40M OpEx reduction on-track by July 2024 as committed in Q3 '23

DESPITE REVENUE SHORTFALL, TEAM CONTINUES TO DELIVER ON CONTROLLING COSTS AND MAINTAINING CASH POSITION

Continued Significant Cash Position



First Quarter 2024

- Cash balance at 3/31/24 of approximately $308M; +$3M vs Q1 ‘23
- Despite revenue shortfall, team continues to focus on cash preservation efforts
- Stable cash position over last seven quarters

AMARIN SECURES SHAREHOLDER APPROVAL FOR SHARE REPURCHASE PROGRAM OF UP TO $50 MILLION; UK HIGH COURT APPROVAL NEXT STEP

- Company has entered into a conditional share repurchase agreement with Cantor Fitzgerald to purchase up to $50 million of Amarin's ordinary shares.
- Program received Amarin shareholder approval at Annual General Meeting in April; now moves to UK High Court for approval, as required under UK company law.
- Amarin anticipates that all required steps will be completed by the end of the second quarter of 2024 with repurchases commencing shortly thereafter.

05 CLOSING & Q&A

Patrick Holt, President & CEO

Q1 2024 Business Highlights

- ✓ **European IP Extended to 2039**
  - Provides Longer Runway to Reach Total Addressable Market & Maximize Commercial Opportunity and Value for VAZKEPA
- ✓ **Europe: Continued Growth Q1 '24 vs. Q4 '23; Pricing & Reimbursement Efforts Advancing**
  - ~35% Revenue Growth; ~65% In-Market Sales Growth Q1 '24 vs. Q4 '23, led by Spain & UK
- ✓ **Continued Focus on Profitability and Cash Preservation; Quarter-End Cash Position of $308 million**
  - Stable cash position over last seven quarters
- ✓ **Secured shareholder approval for share repurchase program of up to $50 million; expected U.K. High Court approval and share repurchases commencing in Q2**

Fundamentals Support Our Progress:

VASCEPA/VAZKEPA Science | Global Opportunity to Impact CV Patients | Dedicated Amarin Team | Strong Balance Sheet

Q&A

Vascepa® (icosapent ethyl)

Vazkepa® (icosapent ethyl)

THANK YOU

AMARIN®